Latest News and Press Releases

The results of the Phase 2 SPRING trial assessing nebokitug in patients with primary sclerosing cholangitis were published in Gastroenterology,

CEO Dr. Adi Mor will present a corporate overview and meet with investors at Oppenheimer's Movers in Rare Disease Summit on Dec. 11, 2025 in NYC.

In the 3rd quarter Chemomab advanced preparations for initiating the Phase 3 trial of nebokitug in PSC, with FDA and EMA aligning on overall study design.

Chemomab announced three presentations "of distinction" at AASLD The Liver Meeting® 2025 featuring clinical data from the nebokitug Phase 2 trial in PSC.

Phase 3 preparations are ongoing while Chemomab is advancing partnering options for executing the nebokitug Phase 3 program. Runway through end of Q2 2026.

FDA agreement on CMC requirements and the timing of non-clinical toxicology testing are milestones further advancing nebokitug towards a PSC Phase 3 trial.

New patents in China and Russia further strengthen nebokitug's extensive intellectual property portfolio in the US, Europe and other major territories.

Clinical data on Chemomab's nebokitug for the treatment of PSC will be presented at the scientific conferences DDW25; EASL 2025 and BSG LIVE'25

David Weiner, MD, is rejoining Chemomab as Interim Chief Medical Officer and Clinical Development SVP Jack Lawler has been named Chief Development Officer.